<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092195</url>
  </required_header>
  <id_info>
    <org_study_id>100083</org_study_id>
    <secondary_id>10-H-0083</secondary_id>
    <nct_id>NCT01092195</nct_id>
  </id_info>
  <brief_title>Gardasil Vaccination in Post Stem Cell Transplant Patients</brief_title>
  <official_title>A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients With and Without Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

        -  Gardasil , a recently approved vaccine for the sexually transmitted human papillomavirus
           (HPV), provides immunity to four types of HPV that are associated with genital warts and
           cervical, vaginal, and vulvar precancer and cancer. The vaccine has been shown to be
           highly effective in preventing infection with these HPV types and was approved for use
           by the Food and Drug Administration.

        -  More research is needed about the vaccine s ability to induce immunity in individuals
           with suppressed immune systems, such as those who have had other kinds of cancer
           treatment such as stem cell transplant. Genital warts, precancer, and cancer have been
           reported as a late complication after stem cell transplant. Researchers are interested
           in determining whether the HPV vaccine is safe to give and able to induce immunity in
           female stem cell transplant recipients, their female donors, and healthy female
           volunteers.

      Objectives:

      - To assess the safety and immune response of the HPV vaccine in female recipients of stem
      cell transplants who are either off or on stable doses of immunosuppression.

      Eligibility:

        -  Females between 18 and 50 years of age who have had allogenic stem cell transplants.

        -  Healthy female volunteers, including stem cell donors, are also eligible for this study.

      Design:

        -  Participants will be screened with a physical examination, blood and urine tests, and
           saliva samples, and will be asked to complete a sexual quality of life questionnaire.

        -  Sexually active participants will also have a routine gynecologic evaluation.

        -  Participants will receive three HPV vaccinations according to the standard vaccination
           schedule (with the second and third following 2 and 6 months after the first).
           Participants will record their daily temperature and any reactions to the vaccine on a
           vaccine report card for 1 week after each vaccination.

        -  Participants will have clinic visits for further testing 2, 6, 7, and 12 months after
           receiving the first HPV vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HPV associated genital dysplasia is a complication following hematopoietic allogeneic stem
      cell transplantation (HSCT). In a recent study from this institution, one third of female
      transplant recipients had HPV related genital tract dysplasia. The quadrivalent human
      papillomavirus virus (HPV) (types 6, 11, 16, 18) vaccine (Gardasil ) is now approved for use
      in females aged 9-26 for the prevention of cervical cancer and, more recently, vulvar and
      vaginal cancer. In this study, Gardasil will be used in females age 18 years to 50 at least
      90 days post stem cell transplant in two study cohorts to determine its safety and
      immunogenicity in this population, as a first step to reduce post-transplant HPV-related
      co-morbidity, genital dysplasia and malignancy. The two study cohorts will both be post
      transplant; one off of immunosuppression (n=24), and one on immunosuppression (n=24).
      Gardasil will be administered using the FDA approved regimen of 3 separate 0.5ml
      intramuscular injections at 0, 2, and 6 months. The primary objectives of this study are to
      determine the safety and immunogenicity of Gardasil in female allogeneic HSCT recipients. A
      cohort of healthy subjects will also be vaccinated (n=24) and will serve as a control.
      Immunogenicity studies characterizing the CD4 and CD8 T- cell response, change in antibody
      titer and cytokine response from baseline to months seven and twelve will be compared in the
      three cohorts. Additionally, genital exams will be performed to monitor for HPV. Secondary
      endpoints will characterize sexual function post-transplant and vulvar/vaginal
      graft-versus-host disease (GVHD). When available, healthy female stem cell donors
      corresponding to enrolled vaccine recipients will be enrolled (n=10) as part of the healthy
      cohort and vaccinated to determine whether there are differences in HPV vaccine
      immunogenicity in a subset of donors and their respective allogeneic, HSCT female recipients.

      As stem cell transplant becomes more applicable to the general population with newer
      transplant techniques allowing for a larger donor pool and as survival improves, problems
      associated with long term survivorship such as genital dysplasia, will become more prevalent.
      Vaccine therapy to prevent or eradicate this disease is needed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2010</start_date>
  <completion_date type="Actual">July 19, 2016</completion_date>
  <primary_completion_date type="Actual">July 19, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Who Developed Antibody Response to the Vaccine.</measure>
    <time_frame>12 months</time_frame>
    <description>The percentage of subjects who developed antibody response to the quadrivalent HPV (qHPV) vaccine (HPV - 6/ - 11/ - 16/ - 18). Anti-HPV-6/11/16/18-specific antibody responses using L1 Virus Like Particle (VLP) ELISA were measured in serum.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Gardasil Vaccine</condition>
  <condition>Stem Cell Transplant</condition>
  <condition>Immunogenicity</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Female subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Female subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil</intervention_name>
    <description>3 separate 0.5 ml intramuscular</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Female stem cell transplant recipient at least 90 days post stem cell transplant

        OR

        Female stem cell transplant recipient at least 90 days post HSCT and on immunosuppression

        OR

        The matched female stem cell transplant donor for an included stem cell transplant
        recipient

        OR

        Healthy female subject

        Age greater than or equal to 18 years and less than or equal to 50 years

        EXCLUSION CRITERIA:

        Vaccine Recipient:

        Obvious HPV condyloma or obvious severe dysplasia (greater than or equal to CIN II)
        warranting treatment

        History of severe adverse reaction to any components (yeast, eggs, monosodium glutamate or
        neomycin) of the quadrivalent HPV vaccine.

        Untreated or persistent life-threatening infections not controlled by current treatment

        Uncontrolled chronic GVHD i.e. highly active eGVHD requiring immediate intervention

        Pregnant or breast feeding or unwilling to be abstinent or practice effective contraception
        during the study period (note: patients who have been rendered infertile with total body
        irradiation are eligible)

        Enrollment in another vaccine clinical trial during the study period

        Enrollment of healthy volunteer in a drug clinical trial during the study period

        Inability to comprehend the investigational nature of the study and provide informed
        consent&lt;TAB&gt;

        Prior Gardasil or other HPV vaccination

        Persistent or recurrent malignancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard W Childs, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2010-H-0083.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27.</citation>
    <PMID>12571259</PMID>
  </reference>
  <reference>
    <citation>Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 1988;10:122-63. Review.</citation>
    <PMID>2852116</PMID>
  </reference>
  <reference>
    <citation>Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis. 2004 Dec;31(12):748-52.</citation>
    <PMID>15608590</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <results_first_submitted>June 11, 2019</results_first_submitted>
  <results_first_submitted_qc>June 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2019</results_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Women's Health</keyword>
  <keyword>Genital Precancer</keyword>
  <keyword>Stem Cell Donor</keyword>
  <keyword>Cervical Cytology</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transplant With Immunosuppression</title>
          <description>Subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Transplant With no Immunosuppression</title>
          <description>Subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Healthy Volunteer</title>
          <description>Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transplant With Immunosuppression</title>
          <description>Subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Transplant With no Immunosuppression</title>
          <description>Subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Healthy Volunteer</title>
          <description>Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Developed Antibody Response to the Vaccine.</title>
        <description>The percentage of subjects who developed antibody response to the quadrivalent HPV (qHPV) vaccine (HPV - 6/ - 11/ - 16/ - 18). Anti-HPV-6/11/16/18-specific antibody responses using L1 Virus Like Particle (VLP) ELISA were measured in serum.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transplant With Immunosuppression</title>
            <description>Subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Transplant With no Immunosuppression</title>
            <description>Subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Healthy Volunteer</title>
            <description>Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Developed Antibody Response to the Vaccine.</title>
          <description>The percentage of subjects who developed antibody response to the quadrivalent HPV (qHPV) vaccine (HPV - 6/ - 11/ - 16/ - 18). Anti-HPV-6/11/16/18-specific antibody responses using L1 Virus Like Particle (VLP) ELISA were measured in serum.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Transplant With Immunosuppression</title>
          <description>Subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Transplant With no Immunosuppression</title>
          <description>Subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
        </group>
        <group group_id="E3">
          <title>Healthy Volunteer</title>
          <description>Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pamela Stratton MD</name_or_title>
      <organization>National Institutes of Health</organization>
      <phone>301-435-4068</phone>
      <email>strattop@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

